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*Graphical Abstract (pictogram)
Click here to download high resolution image
Gold-coated iron oxide nanoparticles with tethered platinum drug have been developed in an effort 
to  produce a means of directing the movement and localisation of drugs in chemotherapy directly 
to the sites of solid tumours using external magnetic fields. 
*Graphical abstract (synopsis)
 Gold-coated iron oxide nanoparticles have been synthesised to which the active component 
of cisplatin has been attached. 
 The nanoparticles are highly cytotoxic in the ovarian carcinoma cell lines A2780 and 
A2780/cp70. 
 The nanoparticles can be controlled and moved by an external magnetic field to site 
specifically inhibit cancer cell growth. 
 The results demonstrate a potential ability to direct drugs in the human body in cancer 
treatment, thus greatly reducing the severity of drug side-effects. 
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2 
Abstract 30 
The platinum-based chemotherapeutic drug cisplatin is highly effective in the treatment of solid 31 
tumours, but its use is restricted by poor bioavailability, severe dose-limiting side effects and rapid 32 
development of drug resistance. In light of this we have tethered the active component of cisplatin to 33 
gold-coated iron oxide nanoparticles to improve its delivery to tumours and increase its efficacy. Iron 34 
oxide nanoparticles (FeNPs) were synthesised via a co-precipitation method before gold was reduced 35 
onto its surface (Au@FeNPs). Aquated cisplatin was used to attach {Pt(NH3)2} to the nanoparticles by a 36 
thiolated polyethylene glycol linker forming the desired product (Pt@Au@FeNP). The nanoparticles 37 
were characterised by dynamic light scattering, scanning transmission electron microscopy, UV visible 38 
spectrophotometry, inductively coupled plasma mass spectrometry and electron probe microanalysis. 39 
The nanoparticles increase in size as they are constructed, with the synthesised FeNPs having a diameter 40 
of 5-50 nm, which increases to 20-80 nm for the Au@FeNPs, and to 60-120 nm for the Pt@Au@FeNPs. 41 
Nanoparticle drug loading was found to be 7.9 × 10
-4
 moles of platinum per gram of gold. The FeNPs 42 
appear to have little inherent cytotoxicity, whereas the Au@FeNPs are as active as cisplatin in the 43 
A2780 and A2780/cp70 cancer cell lines. More importantly the Pt@Au@FeNPs are up to 110-fold more 44 
cytotoxic than cisplatin. Finally, external magnets were used to demonstrate that the nanoparticles could 45 
be accumulated in specific regions and that cell growth inhibition was localised to those areas.46 
  
3 
1. Introduction 47 
Cisplatin, cis-diamminodichloridoplatinum(II), is the most effective platinum based drug for the 48 
treatment of solid tumours [1-3]. It is indicated first line in malignancies of the lung, ovary, head and 49 
neck, bladder and cures over 90% of testicular cancers [1]. Cisplatin is activated when it enters the cell 50 
and subsequently binds directly to DNA, disrupting replication and transcription, which triggers an 51 
apoptotic response [1]. Following injection of cisplatin, most of the drug is excreted renally with only a 52 
fraction of the remaining dose converted to the active diaquo-platinum form [1], limiting the amount of 53 
drug that actually binds to DNA. The use of cisplatin is also restricted due to intrinsic and acquired 54 
resistance caused by reduced drug uptake and efflux, increased detoxification via thiol-containing 55 
biomolecules, and increased DNA repair [1, 4, 5]. Additionally, it displays significant dose-related side 56 
effects such as nephrotoxicity, neurotoxicity, and nausea and vomiting, which can be attributed to its 57 
indiscriminate attack on both healthy and cancerous cells [6].  58 
 59 
Nanoparticle-based drug delivery vehicles have the ability to overcome some of these limitations by 60 
passively or actively targeting tumours. The disorganised vasculature and absence of effective lymphatic 61 
drainage in solid tumours allows nanoparticles to leak from the blood stream and accumulate in the 62 
cancer, a phenomenon known as the Enhanced Permeability and Retention (EPR) effect [7]. This allows 63 
nanoparticles to target tumours passively, reducing uptake into healthy cells.  64 
 65 
Recently, tumour targeting using magnetic fields to direct the movement and localisation of drugs to 66 
solid tumours has generated much interest [8]. Magnetic nanoparticles offer the benefit of utilising both 67 
the EPR effect (passive targeting) whilst also ensuring a direct, guided delivery to the tumour (active 68 
targeting). Nanoparticles of iron oxide possess superparamagnetic properties, whereby magnetism is 69 
only present when under direct energy from an external magnetic field [9]. Other advantages of iron 70 
oxide include its ability to be used in magnetic resonance imaging and induce cytotoxicity through near 71 
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infrared induced hyperthermia [10]. Unfortunately, iron oxide alone in physiological media is unstable, 72 
resulting in oxidation, aggregation and precipitation [10-13]. Moreover, it is a challenge to attach 73 
molecules to the surface of iron oxide. On attachment of cisplatin to iron oxide nanoparticles, it was 74 
observed that the drug rapidly dissociated due to inefficient binding [14]. In vivo, this may result in 75 
early release of cisplatin whilst still in the blood stream and failure of the drug to reach the tumour [14]. 76 
Similar fast release of cisplatin from iron oxide nanoparticles has been observed in a number of other 77 
studies as well [15, 16]. There is therefore a need to develop safer, more stable iron oxide nanoparticles 78 
that can retain platinum drugs more strongly on their surfaces. 79 
 80 
The use of gold nanoparticles as chemotherapeutic drug delivery vehicles is attractive as it is non-toxic, 81 
non-immunogenic, and provides a highly tunable surface to which drugs can be attached [17-19]. 82 
Previously we demonstrated that the active components of cisplatin and oxaliplatin can be tethered to 83 
gold nanoparticles with a drug loading of up to 60,000 cisplatin-like molecules per nanoparticle [20, 84 
21]. In addition, the oxaliplatin-nanoparticle conjugate showed a 6-fold increase in cytotoxicity 85 
compared with the drug alone [20]. We have also demonstrated that the gold nanoparticles can be 86 
reproducibly made and are relatively stable in solution; important features for their pharmaceutical 87 
approval as drug delivery vehicles [21]. Other platinum drugs have also been successfully attached to 88 
other gold-based nanoparticles, where cellular uptake and cytotoxicity was increased compared with the 89 
free drug [22, 23].  90 
 91 
By using both iron oxide and gold within the one drug delivery vehicle, a multifaceted system can be 92 
developed which exploits the surface chemistry of the gold whilst retaining the magnetic character of 93 
the iron oxide, allowing for biologically sound drug delivery and imaging. Lin et al. has demonstrated 94 
that a gold shell did not degrade the magnetic properties of their iron oxide nanoparticles [24]. A study 95 
whereby doxorubicin was successfully loaded onto gold-coated iron nanoparticles (Au@FeNPs) saw the 96 
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same retention of magnetism and a sustained release of the drug [25]. Additionally, iron oxide and gold 97 
have been used in drug delivery and imaging to form dumbbell-like particles; these studies 98 
demonstrated attachment of a range of molecules to the nanoparticles and steady drug release profiles 99 
[26, 27]. 100 
 101 
Taking the theme of this special issue (Metals in Medicine) to its limits, in this paper we give the first 102 
example of platinum anticancer drug delivery using gold-coated iron oxide nanoparticles (Figure 1). The 103 
nanoparticles have been fully characterised using dynamic light scattering (DLS), scanning transmission 104 
electron microscopy (STEM), UV visible spectrophotometry, inductively coupled plasma mass 105 
spectrometry (ICP-MS), and electron probe microanalysis (EPMA). Their cytotoxicity was evaluated 106 
using in vitro growth inhibition assays with the human ovarian cancer cell lines A2780 and A2780/cp70 107 
and the localisation of the nanoparticles to effect site specific growth inhibition has been demonstrated 108 
using an external bar magnet. 109 
 110 
Figure 1. The nanoparticle-based drug delivery system of gold-coated iron oxide nanoparticles 111 
functionalised with a thiolated polyethylene glycol (PEG) linkers to which the active component of the 112 
anticancer drug cisplatin, {Pt(NH3)2}
2+
, is attached via the terminal carboxylate groups. 113 
 114 
 115 
2.0 Results and discussion 116 
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2.1 Nanoparticle synthesis  117 
The synthesis of magnetite-based (Fe3O4) iron oxide nanoparticles is well established in the literature 118 
[13, 28]. The two most common methods for production are non-aqueous thermal decomposition and 119 
aqueous co-precipitation [29, 30]. In synthesising our nanoparticles, we first made Fe3O4 cores by 120 
adding NaOH to a solution of iron(II) and iron(III) chloride salts, hence utilising the co-precipitation 121 
method. The concentration and type of salts, the solution’s pH and ionic strength, all contribute to the 122 
size and character of the nanoparticles created [31]. Recent literature has shown the oxidised maghemite 123 
form (-Fe2O3) preferentially binds gold compared with the magnetite form [11], and is a more stable 124 
and biocompatible form of iron oxide [31, 32]. Subsequently we used nitric acid as an oxidising agent to 125 
convert the Fe3O4 nanoparticles to the -Fe2O3 form (from here onwards referred to as FeNPs) [33]. Iron 126 
oxide nanoparticles are known to be unstable in solution as their agglomeration and aggregation 127 
promote particle growth, inhibiting the formation of the gold shells on their surface. Addition of 128 
tetramethylammonium hydroxide (TMAOH) facilitated dispersion of the our FeNPs, thus inhibiting 129 
aggregation and enforcing solution stabilisation through interaction between the N(CH3)
4+
 cations and 130 
the hydroxide anions that are absorbed onto the FeNP’s surface [11, 34].  131 
 132 
Initial attempts to produce a gold coating onto the FeNPs with glucose as the reducing agent, which has 133 
been used by others, saw no development of the purple/pink colour associated with metallic gold and no 134 
change in the UV spectrum, indicating that this method was unsuccessful. Instead, mixing the FeNPs 135 
with citrate anions allowed for an exchange of the adsorbed hydroxide ions [35]. Drop wise addition of 136 
HAuCl4 with strong heating was then used to ensure the gold coated the iron, rather than expand its own 137 
seeds and create pure gold nanoparticles. At the end of the reaction, the presence of a purple/pink 138 
solution was indicative of a gold coating on the nanoparticles [11, 36, 37]. Pure gold nanoparticles, 139 
which may form during the coating of the FeNPs, were separated from the Au@FeNPs by use of an 140 
external magnet (Figure 2).  141 
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 142 
Figure 2. Photographic images of (a) gold-coated iron nanoparticles (Au@FeNP) demonstrating the 143 
purple colour associated with the presence of metallic gold and (b) the magnetic separation of the 144 
Au@FeNPs which leaves in solution any pure gold nanoparticles which form during the coating of the 145 
FeNPs. 146 
 147 
 148 
Next, a polyethylene glycol (PEG) linker was tethered to the Au@FeNPs. Polyethylene glycol is a 149 
highly flexible and hydrophilic molecule, and has widespread pharmaceutical use due to its stability and 150 
lack of toxicity [38, 39]. Coatings of PEG on nanoparticles, polymers and liposomes can increase 151 
circulation time, improve particle stability, and when thiolated, has strong surface interactions with 152 
metallic gold creating a robust monolayer on the nanoparticles. The particular PEG linker and tethering 153 
method used here was developed and used by us previously [20, 21]. The PEG possesses a strong 154 
stabilising linkage that is hydrophobic on the inner core which then converts to hydrophilic on the outer 155 
part of the sphere, making it compatible with an aqueous environment. PEGylation of the Au@FeNPs 156 
was achieved via gentle shaking of the nanoparticles and the linker overnight, before unbound PEG 157 
linker was removed by use of an external magnet. 158 
 159 
The final step in the synthesis of the nanoparticle system was the attachment of the platinum drug. The 160 
active component of cisplatin, {Pt(NH3)2}
2+
,  was coupled to the surface of the PEGylated nanoparticles 161 
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using aquated cisplatin, [Pt(H2O)2(NH3)2]
2+
 and gentle shaking overnight. N,N-diisopropylethylamine 162 
(DIPEA) was used to deprotonate the carboxylic acid groups on the PEG, allowing the platinum drug to 163 
attach through strong coordination bonds, rather than weaker ionic interactions or host-guest chemistry, 164 
which alternatively has been used for platinum drugs in other systems [40-42]. Washing and magnetic 165 
separation produced the desired platinum drug tethered gold-coated iron oxide nanoparticles 166 
(Pt@Au@FeNP). 167 
 168 
2.2. Nanoparticle Characterisation 169 
 170 
Qualitative characterisation of the nanoparticles was accomplished by UV-visible spectrophotometry 171 
and electron probe microanalysis (EPMA) to assess the elemental presence of iron, gold and platinum. 172 
Inductively coupled plasma mass spectrometry (ICP-MS) was used to determine quantitatively the gold 173 
and platinum content. Scanning transmission electron microscopy (STEM) was used to determine 174 
nanoparticle size, morphology and dispersity. 175 
 176 
The UV spectra of the four stages of nanoparticle synthesis: FeNPs, Au@FeNPs, PEGylated 177 
Au@FeNPs and Pt@Au@FeNPs are shown in Figure 3. The FeNPs absorb strongly up to 178 
approximately 500 nm. Upon addition of the gold coating, the strong absorption is still seen with the 179 
addition of a slight peak at ~560 nm, which is consistent with the presence of metallic gold [43]. Small 180 
diameter gold nanoparticles (i.e. ~ 15 nm) are usually observed by a peak at approximately 520 nm [43]; 181 
the observed peak at 560 nm is broad and shifted away from this wavelength due to the dielectric effect 182 
of the iron oxide. As the depth of gold coating increases in size, the iron interrupts the signal less and the 183 
peak shifts closer to 520 nm [11]. Finally, the presence of platinum is indicated by the sharp peak at 184 
approximately 220 nm [21].  185 
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 186 
Figure 3. UV-visible spectra of the four nanoparticles: FeNP (blue), showing its strong absorption 187 
below 500 nm; Au@FeNP (orange) showing a small peak around 560 nm consistent with metallic gold; 188 
PEGylated Au@FeNP (green); and Pt@Au@FeNP (purple) showing the very strong absorption by 189 
platinum around 220 nm which swamps the absorption peaks of the iron oxide core and the gold 190 
coating. Note: different concentrations of each nanoparticle type have been used to show all peaks on 191 
scale. 192 
 193 
Confirmation of the presence of each element in Pt@Au@FeNPs was achieved by EPMA (Figure 4). 194 
The elements iron (6.4 and 7.09 keV), gold (2.12 and 2.21 keV) and platinum (2.05 and 2.13 keV) were 195 
detected at each respective position. The relative intensities of the peaks indicate a descending 196 
concentration of iron, gold and platinum; as the iron oxide core constitutes the bulk of the nanoparticle 197 
system, accordingly it possesses the maximum elemental counts. The gold coating is thinner than the 198 
iron oxide core but considerably more abundant than the drug molecules attached and thus the platinum 199 
is consequently of significantly lower intensity. Accurate concentrations could not be determined using 200 
this technique due to the scattering effects of the round surfaces of the nanoparticles.  201 
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 202 
Figure 4. The electron probe microanalysis spectrum of Pt@Au@FeNPs, showing the presence of iron, 203 
gold and platinum. Scattering effects from the nanoparticles means accurate concentrations of each 204 
respective element cannot be determined. 205 
 206 
 207 
Determination of the particle’s sizes was initially attempted using dynamic light scattering although this 208 
did not prove successful due to sedimentation and/or aggregation of the particles, particularly the 209 
FeNPs; as the gold and PEG layers were attached the particles become easier to suspend in solution. In 210 
many samples a non-reproducible, bimodal distribution (not shown) was seen and it is known that DLS 211 
determined particle sizes can be affected by even the smallest amounts of aggregation in a sample [44]. 212 
Instead, scanning transmission electron microscopy (STEM) was used to determine particle sizes.  213 
 214 
Table 1. The approximate sizes as each type of nanoparticle as determined by STEM.  215 
Nanoparticle Diameter Range (nm) 
FeNP 5-50 
Au@FeNP 20-80 
Pt@Au@FeNP 60-120 
 216 
From the STEM images, particle size distributions can be determined (Table 1). A size range of 5-50 nm 217 
was observed for the FeNPs. Whilst most of the particles had sphere-like shapes, some samples also 218 
contained rod-like structures, a phenomenon also observed by Kang et al. [45].  Reduction of the gold 219 
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coating onto the FeNPs results in an increase in the size of the nanoparticles to 20-80 nm. The gold 220 
coating of the Au@FeNPs is observed in the STEM images as a lightened area around the much darker 221 
iron oxide core (Figure 5). Attachment of the PEG linker and platinum drug increases the nanoparticle’s 222 
size to 60-120 nm (Table 1).  223 
                                                      224 
Figure 5. A scanning transmission electron microscope image of Au@FeNPs, showing the dark iron 225 
oxide core surrounded by the more transparent gold-coating. 226 
 227 
The concentration of gold and platinum in the Pt@Au@FeNPs was quantified by ICP-MS. Each 228 
individual sample of nanoparticles contains a slightly different amount of gold and platinum, although 229 
from multiple batches there appears to be an 85% correlation between the two; increasing gold coating 230 
increases the platinum loading of the nanoparticles. The variations in concentration can arise due to 231 
slight changes in the method used to produce the gold-coating and the incubation time used to react the 232 
aquated cisplatin with the PEGylated Au@FeNPs. The concentrations obtained by ICP-MS correlate to 233 
the counts produced by EPMA (see Figure 4).  Overall the loading of platinum in Pt@Au@FeNPs is 7.9 234 
× 10
-4
 moles of platinum per gram of gold. The highest concentration of platinum obtained for the 235 
nanoparticles solutions was 8.372 µM, which is more than 50-fold higher than what we could achieve 236 
previously for pure gold-only nanoparticles: 0.135 µM platinum [21]. 237 
 238 
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 239 
2.3 In vitro cytotoxicity 240 
The cytotoxicity of the three different nanoparticles was examined using in vitro growth inhibition 241 
assays with the human ovarian carcinoma cell line A2780 and its cisplatin resistant cell line 242 
A2780/cp70. Cisplatin displays micromolar levels of cytotoxicity in the sensitive cell line and is 243 
approximately 10-fold less active in the resistant cell line. Iron oxide nanoparticles are not known to be 244 
inherently cytotoxic and in our studies no cytotoxicity was observed at concentrations up to 2 μM (note: 245 
this concentration is approximate as no reliable way of determining FeNP concentration could be found 246 
in the literature nor developed by us). The Au@FeNPs display good inherent cytotoxicity with a similar 247 
IC50 as cisplatin in the sensitive cancer cell line, but is 4.3-fold more active than cisplatin in the resistant 248 
line. Most importantly, the cisplatin tethered nanoparticles demonstrate activity at nanomolar 249 
concentrations and are 110-fold more active than cisplatin in A2780. This is consistent with our earlier 250 
work where oxaliplatin-based drug molecules tethered to pure gold nanoparticles were highly cytotoxic 251 
[20]. Unfortunately the cisplatin Pt@Au@FeNPs, despite having activity at nanomolar concentrations, 252 
are cross-resistant with cisplatin in A2780/cp70.  253 
 254 
Table 2. The in vitro cytotoxicity of the nanoparticles in the human ovarian carcinoma cell line A2780 255 
and its cisplatin resistant sub-line A2780/cp70. Resistance factor (Rf) is defined as the IC50 of the 256 
complex in the resistant line divided by the IC50 of the complex in the sensitive line; any complex with 257 
an Rf less than 1 is considered able to overcome cisplatin resistance. 258 
Compound 
IC50 (μM) 
Rf 
A2780 A2780/cp70 
Cisplatin 0.527 ± 0.099 5.06 ± 0.53 9.6 
FeNP >2 >2 N/A 
Au@FeNP 0.742 ± 0.148 1.62 ± 0.16 2.2 
Pt@Au@FeNP 0.00467 ± 0.0008 0.0293 ± 0.041 6.3 
 259 
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One of the key goals of developing the iron oxide-based nanoparticles was the development of a drug 260 
delivery system that could be used to direct treatment more accurately to the sites of solid tumours by 261 
use of an external magnetic field. It was therefore important to determine whether the Pt@Au@FeNPs 262 
could be magnetically controlled in a biological environment and if localisation of the nanoparticles 263 
could induce site specific cell growth inhibition. 264 
 265 
Cisplatin sensitive A2780 cells were grown as a monolayer in culture and treated with Pt@Au@FeNPs. 266 
The cells were then incubated in the presence of bar magnets placed under the dishes. At the conclusion 267 
of the experiment the cells were washed and stained for direct visualisation. As can be seen in figure 6, 268 
the nanoparticles were attracted to the poles of the bar magnet and the localisation that this produced 269 
resulted in growth inhibition of the cancers cells in these specific regions. 270 
 271 
Figure 6. A representative photograph of a plate of monolayer cultured A2780 cancer cells after 272 
treatment with Pt@Au@FeNPs (12 nM) showing the growth inhibition zones from a bar magnet placed 273 
underneath the dish. The inhibition zones represent the north and south poles of the magnet to which the 274 
nanoparticles are most highly attracted. 275 
 276 
3.0 Conclusions 277 
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Here we have successfully designed, synthesised and characterised a novel nanoparticle drug delivery 278 
system for platinum-based anticancer drugs. The nanoparticles were characterised by a number of 279 
techniques, which demonstrated a system containing a gold-coating over an iron oxide core to which the 280 
active component of cisplatin was attached using a thiolated PEG linker. These nanoparticles could be 281 
controlled and moved with an external magnetic field, allowing drug release to be localised to a specific 282 
area. Potentially, this technology could be used in patients to ensure drugs are targeted only to solid 283 
tumours, thereby leaving healthy tissue/organs intact and greatly reducing the side-effects associated 284 
with chemotherapy. The technology developed here can now be used to design further nanoparticle 285 
systems, which can examine the application of different platinum drugs, different tethering linkers and 286 
different shaped/size nanoparticles. 287 
 288 
 289 
4.0 Methods 290 
4.1 Materials.  All chemicals and solvents were purchased from Sigma-Aldrich, except iron(III) 291 
hexahydrate and HAuCl4, which were purchased from Fisher Scientific.  All aqueous solutions were 292 
prepared using water filtered by a Millipore purification unit.  Aquated cisplatin was made by reacting 293 
the drug with two mole equivalents of AgNO3 in the dark for 48 h, before the resultant AgCl was 294 
removed using a 0.2 µm nylon filter. The PEG linker was made as previously described [20].  295 
 296 
4.2 Inductively coupled plasma – mass spectrometry. All samples were digested in aqua regia (3:1 297 
HCl:HNO3) and diluted in water to a final acid content of 2%. An Agilent 7700X instrument, with 298 
a micromist nebuliser and an octapole collision cell, was calibrated using solutions prepared from a 299 
Spex CertPrep platinum standard at concentrations ranging from 0 – 1000 ppb, containing 2% nitric 300 
acid.  Platinum concentration was determined using the 
195
Pt isotope.  Instrument operating conditions 301 
used were: 1,550W RF forward power, 0.85 L min
-1
 plasma carrier gas flow, 0.2 L min
-1
 makeup gas 302 
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flow, 4.6 mL min
-1
 helium gas flow in the collision cell and 0.1 rps for the nebulizer pump.  Sample 303 
depth was 8 mm, sample period was 0.31 s and integration time was 0.1 s. 304 
 305 
4.3 Dynamic light scattering. Dynamic light scattering and zeta potential experiments were conducted 306 
on a Malvern Zetasizer Nano ZS. The machine was calibrated using a 60 nm polystyrene standard. Each 307 
1 mL sample was loaded into a cell and particle size and zeta potential were measured simultaneously 3 308 
times with triplicate samples. 309 
 310 
4.4 Scanning transmission electron microscopy. Samples of FeNP, Au@FeNP, PEGylated Au@FeNP, 311 
and Pt@Au@FeNP (1 µL) were dried on a silicon substrate and placed under vacuum. TEM images 312 
were collected using a Zeiss ULTRA plus, high resolution Schottky field-emission scanning electron 313 
microscope. An accelerating voltage of 30 kV was applied to each sample. A STEM detector was used 314 
for both brightfield and darkfield images. 315 
 316 
4.5 Ultraviolet-visible spectrophotometry.  UV-visible spectra were obtained using a Varian Cary 50 317 
Bio spectrophotometer running CaryWin UV scan software.  Each sample (2 mL) was prepared at 318 
appropriate dilutions to achieve absorption values between 0 – 1.  Samples were measured in a silica 319 
cuvette (1 cm) and an average of three measurements were used. 320 
 321 
4.6 Electron probe microanalyser. A sample of Pt@Au@FeNPs (1 μL) was dried on a silicon substrate 322 
and placed under vacuum. The wavelength-dispersive X-ray spectrum was acquired in a Cameca SX100 323 
electron probe microanalyser using a pentaerythritol crystal with a lattice spacing of 2d, 8.75 Å at 20 324 
keV, and a 40 nA electron beam. 325 
 326 
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4.7 Synthesis of iron nanoparticles (FeNP).  All glassware used in the preparation of nanoparticles 327 
was soaked in aqua regia for at least 4 h and rinsed with distilled water until the water pH was neutral.  328 
FeCl2 (5.4 g, 0.042 mol) and FeCl3 (2.0 g, 0.013 mol) were dissolved in a three neck round bottom flask 329 
in 20 mL distilled water and HCl (100 µL, 2 M). This was stirred by a double-linked glass stirrer, using 330 
a mechanical stirrer (Janke & Kunkel, Type RW20, speed setting “2”) until the salts dissolved. The 331 
entire pre-synthesised stock solution was added drop wise to NaOH (250 mL, 1.5 M), whilst being 332 
continuously stirred (speed setting “4.5”). The solution turned dark black as the nanoparticles formed. 333 
The FeNPs were collected using a permanent magnet and the supernatant discarded. They were then 334 
washed gradually with HNO3 (400 mL, 0.1 M) and HNO3 (200 mL, 0.01 M) before being suspended in 335 
HNO3 (100 mL, 0.01 M). This solution was heated to 90 
oC and stirred constantly (speed setting “2”) 336 
for 30 min until the solution turned a brown-red colour. After cooling the particles were washed 3 times 337 
with distilled water and separated from the solution using a permanent magnet, and then resuspended in 338 
0.1 M TMAOH. 339 
 340 
4.8 Gold coating of iron oxide nanoparticles (Au@FeNP). Iron oxide nanoparticles (10 mL, unknown 341 
concentration) were added to sodium citrate (100 mL, 0.1 M) in a three neck round bottom flask and 342 
stirred for 30 min (speed setting “5”). The solution was sonicated for 15 min before being heated to 343 
boiling point with a bunsen burner, with continuous heating, 100 µL aliquots of HAuCl4 (15 mL, 1% 344 
w/v) was added every minute. The Au@FeNPs were then separated from any pure gold nanoparticles 345 
using a permanent magnet and washed with distilled water three times before being redispersed in water. 346 
 347 
4.9 Assembly of cisplatin-tethered gold-coated iron oxide nanoparticles (Pt@Au@FeNP). Gold-348 
coated iron oxide nanoparticles (200 µL, unknown concentration), were diluted to 1 mL in a glass vial 349 
by the addition of distilled water (700 µL) and PEG linker (100 µL, 10 mM). This was then placed in 350 
round bottom flask and spun on rotary evaporator for 12 h to form a PEG monolayer on the surface of 351 
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the nanoparticles. Unbound PEG linker was removed using a permanent magnet to separate the 352 
PEGylated Au@FeNPs from the supernatant. The PEGylated nanoparticles were then redispersed in 1 353 
mL distilled water and the purification completed once more. A 0.1 M stock solution of N,N-354 
diisopropylethylamine (DIPEA) was prepared by dissolving 17 µL of the base 1,3-dimethyl-3,4,5-355 
tetrahydro-2(1H)-pyrimidone in 1 mL DIPEA. Of this, 100 µL was added to a glass vial containing PEG 356 
bound gold-coated iron nanoparticles. Aquated cisplatin (2.5 mg) was dissolved in 1 mL 1,3-dimethyl-357 
3,4,5-tetrahydro-2(1H)-pyrimidone and an aliquot (100 μL) of this added to the nanoparticles, before 358 
being gently shaken overnight. Finally, the Pt@Au@FeNPs were separated from the supernatant using a 359 
permanent magnet and washed twice with distilled water before being redispersed in the same medium. 360 
 361 
4.10 Cytotoxicity and drug localisation experiments. In vitro growth inhibition assays were 362 
conducted as previously described [46], with the platinum  and gold concentrations of the nanoparticles 363 
determined using ICP-MS for each individual batch used in the cytotoxicity assays. For the magnetic 364 
susceptibility and localisation experiments A2780 cells were plated at a density of 50,000 cells per 6 cm 365 
petri nunc tissue culture dish and grown for 24 h before the cells were then incubated with 366 
Pt@Au@FeNPs at a concentration of either 6 or 12 nM and in the presence or absence of a bar magnet 367 
(18 × 4 mm). To ensure the magnets did not move and the dishes remained flat during incubation, they 368 
were covered in bubble wrap with the magnets nestled between the bubbles. After 24 h the drug media 369 
was removed and fresh medium added for a further 48 h of incubation. Finally, the dishes were washed 370 
with phosphate buffered saline, fixed twice for 5 min in methanol, dried in air, then stained with crystal 371 
violet for 5 min. Unbound stain was washed off with water before photographic images were obtained. 372 
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